

RECEIVED/REÇU  
SKMD  
SEP 16 2010  
Vet Drugs Directorate  
Direction des Médicaments Vet.



**FORM IV: PATENT LIST**  
**Patented Medicines (Notice of Compliance) Regulations**  
COMPLETE ONE FORM PER PATENT PER SUBMISSION

**PART 1**

PLEASE COMPLETE EITHER SECTION A or B AS APPLICABLE.

A) PATENT LIST IS BEING FILED WITH SUBMISSION (please check **ONE** of the following):

- i) NDS  or;
- ii) SNDS - CHANGE IN FORMULATION
- CHANGE IN DOSAGE FORM
- CHANGE IN USE
- iii) CARRY FORWARD, IN ACCORDANCE WITH SECTION 4.1(2)

B) NEWLY ISSUED PATENT\* FOR LISTING AGAINST PREVIOUSLY FILED SUBMISSION (please identify **ONE** of the following):

- i) NDS SUBMISSION No.: \_\_\_\_\_ or;
- ii) SNDS - CHANGE IN FORMULATION, SUBMISSION No.: \_\_\_\_\_
- CHANGE IN DOSAGE FORM, SUBMISSION No.: \_\_\_\_\_
- CHANGE IN USE, SUBMISSION No.: \_\_\_\_\_
- iii) CARRY FORWARD, IN ACCORDANCE WITH SECTION 4.1(2) \_\_\_\_\_

\* Newly issued patent must be submitted within 30 days of grant in accordance with subsection 4(6).

**PART 2**

MEDICINAL INGREDIENT(S): Spinosad/Milbemycin Oxime	
BRAND NAME: Trifexis	
HUMAN: <input type="checkbox"/> or VETERINARY: <input checked="" type="checkbox"/>	DIN: 023754S1
DOSAGE FORM: Tablet	STRENGTH PER UNIT: 140/2.3, All units are in milligrams (mg).
ROUTE(S) OF ADMINISTRATION: Oral	
USE(S) OF THE MEDICINAL INGREDIENT(S): Prevention of heartworm, treatment and control of adult roundworms ( <i>Toxocara Canis</i> , <i>Toxascaris leonina</i> , <i>Trichuris Vulpis</i> , <i>Ancylostoma Caninum</i> ).	

**PART 3**

PATENT NUMBER	CODE *	CANADIAN FILING DATE OF PATENT APPLICATION (yyyy-mm-dd)	DATE GRANTED (yyyy-mm-dd)	EXPIRATION DATE (yyyy-mm-dd)
2 379 329	C	2000 - 08 - 02	2009 - 10 - 20	2020-08-02
<p>* CODE: "A" : APPLICANT IS THE OWNER OF THE PATENT</p> <p style="padding-left: 20px;">"B" : APPLICANT HAS AN EXCLUSIVE LICENSE</p> <p style="padding-left: 20px;">"C" : APPLICANT HAS OBTAINED THE CONSENT OF THE OWNER OF THE PATENT FOR THE INCLUSION OF THE PATENT ON THE ABOVE PATENT LIST</p>				

**PART 4****PLEASE UPDATE AS REQUIRED**

NAME AND ADDRESS FOR SERVICE IN CANADA:	
Elanco, Division Eli Lilly Canada Inc.	
150 Research Lane, Suite 120	
Guelph, ON N1G 4T2	
Canada	

**PART 5****PLEASE UPDATE AS REQUIRED**

CERTIFICATION: <i>In accordance with paragraph 4(4)(f), I certify that the information included in this Patent List is accurate and that the patent on the list meets the eligibility requirements of subsection 4(2) or 4(3) of the Patented Medicines (Notice of Compliance) Regulations.</i>		
NAME: Dr. Randal Bagg		TITLE: Manager, Research and Regulatory
ADDRESS: 150 Research Lane, Suite 120		
NAME OF MANUFACTURER: Elanco, Division Eli Lilly Canada Inc.		
SIGNATURE: <i>Randal Bagg</i>		DATE: August 20, 2010
CONTACT:	PHONE#: 519-341-7006	FAX#: 519-821-7831

**PART 6**

<b>FOR OFFICE USE ONLY:</b>	
SUBMISSION No.: 141509	DATE OF FILING SUBMISSION: 2010-09-16
NOC DATE: 2011-11-01	DATE ORIGINALLY ADDED: 2015-07-20
DATE AMENDED:	